Michael Brown
Gastroenterology · Dallas, TXNPI 1265903652
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (58.7%), ownership interests and travel and lodging — rather than concentrated in one kind of arrangement. Regeneron accounts for 100.0% of it on its own, with 2 other manufacturers making up the rest. Among gastroenterology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 310 payments — averaging $17,805 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron$5.5M
- Pfizer$28
- Novo Nordisk$18
What the payments were for
- Consulting fees$3,239,75559%
- Travel & lodging$467,6328%
- Food & beverage$12,0280%
- Ownership interest$1,800,08733%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron | 307 | $5,519,457 |
| Pfizer | 2 | $28 |
| Novo Nordisk | 1 | $18 |
How this compares
$5,519,502 in reported general payments places this provider in the 95th percentile of 1,350 gastroenterology providers in Texas.
Other gastroenterology in Dallas
- John FordtranDallas$9.9M
- Parvez MantryDallas$958K
- Jay HortonDallas$326K
- Jacqueline O LearyDallas$157K
- Sami ArslanlarDallas$142K
- Amit DesaiDallas$71K
- Byron CryerDallas$68K
- Bincy AbrahamHouston$1.6M
- Mazen NoureddinHouston$1.5M
- Stephen PappasHouston$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.